INFLUENZAIMPFSTOFF UND THERAPIE
European patent · EP3049112 · In force
Register entry
- Publication number
- EP3049112
- Application number
- EP14845566
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Sep 21, 2014
- Published
- Aug 3, 2016
- Granted
- Sep 9, 2020
- Protection ends at the latest
- Sep 20, 2034
- Next annual fee due
- Sep 30, 2027
- IPC classes
- A61K 39/395 (2006.01)
- Priority
- US 201361881325 P 23.09.2013
- PCT application
- PCT/US2014/056703 21.09.2014
- PCT publication
- WO2015/042498 26.03.2015
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Oct 23, 2026
Next annual fee due on
- Next annual fee due on
- 30.09.2026 → 30.09.2027
Published in Swissreg on 23.10.2026
- Oct 1, 2025
Next annual fee due on
- Next annual fee due on
- 30.09.2025 → 30.09.2026
Published in Swissreg on 01.10.2025
- Oct 3, 2024
Change
Published in Swissreg on 03.10.2024
- Oct 1, 2023
Change
Published in Swissreg on 01.10.2023
- Oct 1, 2022
Change
Published in Swissreg on 01.10.2022
- Mar 12, 2021
Agent entered
- Representative
- BOHEST AG, Holbeinstrasse 36-38, 4051 Basel
Published in Swissreg on 12.03.2021
- Mar 10, 2021
Owner
- Owner
- Engen Bio, Inc., 61 Avondale Avenue, Redwood City, CA 94062, USA → Engen Bio, LLC, 61 Avondale Avenue, Redwood City, CA 94062, USA
Published in Swissreg on 10.03.2021
- Sep 9, 2020
Granted
Published in Swissreg on 09.09.2020
Parties
Inventor
Redwood City, CA 94062, US
San Francisco, CA 94110, US
New York, NY 10532, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.